CLINICAL_TRIALS
trial_result
· 2021-09-16
Clinical Trial Update: Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma [Phase 2]
Summary
Phase 2 trial of belinostat in relapsed or refractory peripheral T-cell lymphoma has completed with results posted in 2021.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Peripheral T-cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2021-09-16